Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Surg Endosc. 2023 Nov;37(11):8316-8325. doi: 10.1007/s00464-023-10355-9. Epub 2023 Sep 7.
Same day discharge (SDD) may be considered in some patients undergoing minimally invasive adrenalectomy (MIA). Recent studies have demonstrated similar outcomes between SDD and admitted patients; however, most excluded pheochromocytoma and adrenal metastases. This study evaluates 30-day complications and hospital readmission in a large cohort of patients undergoing MIA.
Adult patients undergoing MIA (2010-2020) for benign adrenal disorders, pheochromocytoma, and adrenal metastases were identified within the ACS-NSQIP database. Comparisons between patients having SDD versus admission were performed. Factors associated with 30-day complications and unplanned readmission were evaluated by multivariable regression modeling.
Of 7316 patients who underwent MIA, 254 had SDD. Baseline characteristics were similar between groups, although SDD patients had lower ASA class (p < 0.001) and were more likely to undergo MIA for nonfunctioning adenoma or primary aldosteronism (p = 0.001). After adjusting for covariates, higher ASA class and presence of medical comorbidities were associated with increased complications (p < 0.001; p < 0.05) and unplanned readmission (p < 0.001; p < 0.05). Additionally, prolonged operative time was associated with 30-day complications (p < 0.001). Notably, SDD was not associated with increased complications (OR 0.78, 95% CI 0.38-1.61, p = 0.502) or unplanned readmission (OR 0.76, 95% CI 0.35-1.64, p = 0.490). The rate of SDD for MIA increased from 1.48% in 2017 to 10.81% in 2020.
Not all patients undergoing MIA should have SDD; however, the current analysis demonstrates a trend toward SDD and supports its safety in select patients with adrenal metastases and benign adrenal disorders including pheochromocytoma.
在接受微创肾上腺切除术(MIA)的部分患者中,可考虑当天出院(SDD)。最近的研究表明,SDD 与住院患者的结果相似;然而,大多数研究都排除了嗜铬细胞瘤和肾上腺转移瘤。本研究评估了在接受 MIA 的大量患者中 30 天并发症和医院再入院的情况。
在 ACS-NSQIP 数据库中,确定了 2010 年至 2020 年期间因良性肾上腺疾病、嗜铬细胞瘤和肾上腺转移瘤而行 MIA 的成年患者。对 SDD 患者与住院患者进行比较。通过多变量回归模型评估 30 天并发症和计划外再入院的相关因素。
在 7316 例接受 MIA 的患者中,有 254 例患者进行了 SDD。两组患者的基线特征相似,但 SDD 患者的 ASA 分级较低(p<0.001),更有可能因无功能腺瘤或原发性醛固酮增多症而接受 MIA(p=0.001)。在校正协变量后,较高的 ASA 分级和存在合并症与并发症增加(p<0.001;p<0.05)和计划外再入院(p<0.001;p<0.05)相关。此外,手术时间延长与 30 天并发症相关(p<0.001)。值得注意的是,SDD 与并发症增加无关(OR 0.78,95%CI 0.38-1.61,p=0.502)或计划外再入院(OR 0.76,95%CI 0.35-1.64,p=0.490)无关。MIA 行 SDD 的比例从 2017 年的 1.48%增加到 2020 年的 10.81%。
并非所有接受 MIA 的患者都应行 SDD;然而,目前的分析表明 SDD 的趋势,并支持其在某些肾上腺转移瘤和包括嗜铬细胞瘤在内的良性肾上腺疾病患者中的安全性。